7) Not doing ph3 for thyroid but said that if VB-111 is on the market and thyroid patients need the drug then it could be available for them without a need to do a full ph3 for thyroid. Nice to cross that bridge when that happens.
Question: Can VBLT do the same thing mentioned above to the Ovarian without phase 3 trial ? and why would vblt declined the SPA that wad offered to them by the FDA?
News 
Market Data 
Discover 
